An anonymous reader quotes a report from NPR: Women in the U.S. gave birth to roughly 710,000 fewer children last year compared with the nation's peak in 2007, according to preliminary data released (PDF) this week by the Centers for Disease Control and Prevention. Lead researcher Brady Hamilton, a demographer with the CDC's National Center for Health Statistics, said the latest one percent drop in "general fertility" from 2024 to 2025 is part of a long-running downward trend. "Since 2007, there's been a decline in the general fertility rate [in the U.S.] of 23%," Hamilton told NPR.

The impact of that change in real numbers is sizable: In 2007, there were 4,316,233 babies born. Last year, even though the nation's population as a whole is larger, there were only 3,606,400 newborns. There's no consensus over why women and couples have shifted their behavior so significantly. Some experts point to economic factors, others say cultural influences, and better access to education and contraception for women are driving the change. "We're seeing big drops in fertility rates for young women, teenagers and women in their 20s," said economist Martha Bailey, head of the California Center for Population Research at the University of California, Los Angeles. "What's not yet clear is whether or not those same women will go on to have children later on."

"People are having the number of children they want and that they can afford at a time that makes the most sense for them," she said. "What I don't think anyone is in favor of is a Handmaid's Tale type policy regime, where we're trying to talk families into having children they don't want."

One silver lining in the data is the 7% decline in teen pregnancies in 2025. Bianca Allison, pediatrician and associate professor at the University of North Carolina School of Medicine, said: "What is actually affecting the birth rates are likely lower rates of teen pregnancy overall, which is in the context of higher use of contraception and lower sexual activity for youth, and then also continued access to abortion care."

An anonymous reader quotes a report from the Guardian: [Five skilled workers aged 50 and older spoke] to the Guardian about how, after struggling to find work in their fields, they have turned to an emerging and growing category of work: using their expertise to train artificial intelligence models. Known as data annotation, the work involves labeling and evaluating the information used to train AI models like Open AI's ChatGPT or Google's Gemini. A doctor, for example, might review how an AI model answers medical questions to flag incorrect or unsafe responses and suggest better ones, helping the system learn how to generate more accurate and reliable responses. The ultimate goal of training is to level up AI models until they're capable of doing a job as well as a human could -- meaning they could someday replace some of these human workers.

The companies behind AI training, such as Mercor, GlobalLogic, TEKsystems, micro1 and Alignerr, operate large contractor networks staffed by people like Ciriello. Their clients include tech giants like OpenAI, Google and Meta, academic researchers and industries including healthcare and finance. For experienced professionals, AI training contracts can be a side hustle -- or a temporary fallback following a layoff -- where top experts can, in some cases, earn over $180 an hour. But that's on the high end. For some older workers [...], it represents another thing entirely: a last refuge in a brutal job market that is harder to stay in, or re-enter, the older they get. For many of them, whether or not they're training their AI replacements in their professions is besides the point. They need the work now.

[...] "There's just a lot of desperation out there," Johnson said. As opportunities narrow, many turn to what Joanna Lahey, a professor at Texas A&M University who studies age discrimination and labor outcomes, calls "bridge jobs" -- lower-paying, less demanding roles that help workers stay financially afloat as they approach retirement. Historically, that meant taking temp assignments, retail and fast-food work and gig roles like Uber and food delivery. Now, for skilled workers -- engineers, lawyers, nurses or designers, for example -- using their expertise for AI data training is becoming the new bridge job. "[AI] training work may be better in some ways than those earlier alternatives," Lahey told the Guardian.

AI training can offer flexibility, quick income and intellectual engagement. But it's often a clear step down. Professionals in fields such as software development, medicine or finance typically earn six-figure salaries that come with benefits and paid leave, according to the US Bureau of Labor Statistics. According to online job postings, AI training gigs start at $20 an hour, with pay increasing to between $30 and $40 an hour. In some cases, AI trainers with coveted subject matter expertise can earn over $100 an hour. AI training is contract-based, though, meaning the pay and hours are unstable, and it often doesn't come with benefits.

In a new 4,000-word article, CNN tells the story of a retired appellate paralegal and grandmother in her early 70s who was treated for depression with psilocybin. CNN notes there's now retreats featuring psilocybin in a few countries — and while psilocybin is illegal under United States federal law, "In Oregon, 5,935 clients received psilocybin services through Oregon's state-regulated program in 2025." High doses of psilocybin are effective in treating depression, a growing body of research suggests, with promise for other conditions, like PTSD and addiction, said Dr. Albert Garcia-Romeu, associate director of the Center for Psychedelic and Consciousness Research at Johns Hopkins University... Some researchers suggest it disrupts entrenched traffic patterns in the brain or grows new neuron connections to change thinking. Others say the results from psilocybin could have to do with its anti-inflammatory effect, Garcia-Romeu said...

Colorado became the second state to make psilocybin legal with a 2023 law and issued its first healing center" last year. A law adopted in New Mexico last year established that state's Medical Psilocybin Program, now in development... Psilocybin seems to be "knocking on the door of FDA approval," said Dr. Lynn Marie Morski, president of the Psychedelic Medicine Association, which educates health care providers on the therapeutic use of psychedelics so they can answer patients' questions through the lenses of clinical evidence and harm reduction. Psilocybin therapy first received a "breakthrough therapy" designation for treatment-resistant depression from the US Food and Drug Administration in 2018, and now psilocybin drug products are on track to be submitted to the FDA for possible approval in the not-too-distant future.

While psilocybin is illegal under United States federal law, more states are creating their own paths for legal use under state laws.

While AI CEOs worry governments might nationalize AI, others are advocating for something similar. Canadian security professional Bruce Schneier and Harvard data scientist Nathan Sanders published this call to action in Canada's most widely-read newspaper (with a readership over 6 million): "Canada Needs Nationalized, Public AI." While there are Canadian AI companies, they remain for-profit enterprises, their interests not necessarily aligned with our collective good. The only real alternative is to be bold and invest in a wholly Canadian public AI: an AI model built and funded by Canada for Canadians, as public infrastructure. This would give Canadians access to the myriad of benefits from AI without having to depend on the U.S. or other countries. It would mean Canadian universities and public agencies building and operating AI models optimized not for global scale and corporate profit, but for practical use by Canadians...

We are already on our way to having AI become an inextricable part of society. To ensure stability and prosperity for this country, Canadian users and developers must be able to turn to AI models built, controlled, and operated publicly in Canada instead of building on corporate platforms, American or otherwise... [Switzerland's funding of a public AI model, Apertus] represents precisely the paradigm shift Canada should embrace: AI as public infrastructure, like systems for transportation, water, or electricity, rather than private commodity... Public AI systems can incorporate mechanisms for genuine public input and democratic oversight on critical ethical questions: how to handle copyrighted works in training data, how to mitigate bias, how to distribute access when demand outstrips capacity, and how to license use for sensitive applications like policing or medicine...

Canada already has many of the building blocks for public AI. The country has world-class AI research institutions, including the Vector Institute, Mila, and CIFAR, which pioneered much of the deep learning revolution. Canada's $2-billion Sovereign AI Compute Strategy provides substantial funding. What's needed now is a reorientation away from viewing this as an opportunity to attract private capital, and toward a fully open public AI model.
Long-time Slashdot reader sinij has a different opinion. "To me, this sounds dystopian, because I can also imagine AI declining your permits, renewal of license, or medication due to misalignment or 'greater good' reasons."

But the Schneier/Sanders essays argues this creates "an alternative ownership structure for AI technology" that is allocating decision-making authority and value "to national public institutions rather than foreign corporations."

"A surgeon in London says he has performed the UK's first long-distance robotic operation," reports the BBC, "on a patient located 1,500 miles (2,400km) away..." Leading robotic urological surgeon Professor Prokar Dasgupta said it felt "almost as if I was there" as he carried out a prostate removal on [62-year-old] Paul Buxton... It is hoped that remote robotic surgery could spare future patients the "vast expense and inconvenience" of travelling for treatment, and help deliver better healthcare to people in more remote locations... Buxton had expected to be put on an NHS waiting list after receiving a shock prostate cancer diagnosis just after Christmas, but he "jumped at the chance" to be the first patient to undergo the treatment remotely as part of a trial. "A lot of people actually said to me: 'You're not going to do it, are you?'

"I thought, I'm giving something back here," he said...

The operation was performed from The London Clinic using a robot equipped with a 3D HD camera and four arms, all controlled through a console with a delay of only 0.06 seconds. The console in the UK was connected to the robot in Gibraltar via fibre-optic cables, with a backup 5G link. A team in Gibraltar remained on standby in case the connection failed, but it held throughout the procedure...

Dasgupta will perform the procedure again on 14 March, which will be live-streamed to 20,000 world-leading urological surgeons at the European Association of Urology congress. He added: "I think it is very, very exciting, the humanitarian benefit is going to be significant."
The U.K.'s National Health Service "is prioritising local robotic-assisted surgery," the article points out, "aiming for 500,000 robot-supported operations a year by 2035."

Thanks to Slashdot reader fjo3 for sharing the article.

Long-time Slashdot reader fjo3 shared this report from Agence France-Presse: Japan has approved ground-breaking stem-cell treatments for Parkinson's and severe heart failure, one of the manufacturers and media reports said Friday, with the therapies expected to reach patients within months.

Pharmaceutical company Sumitomo Pharma said it received the green light for the manufacture and sale of Amchepry, its Parkinson's disease treatment that transplants stem cells into a patient's brain. Japan's health ministry also gave the go-ahead to ReHeart, heart muscle sheets developed by medical startup Cuorips that can help form new blood vessels and restore heart function, media reports said. The treatments could be on the market and rolled out to patients as early as this summer, reports said, citing the health ministry, becoming the world's first commercially available medical products using induced pluripotent stem cells...

In a statement, Sumitomo Pharma said it had obtained "conditional and time-limited approval" for the manufacture and marketing of Amchepry under a system which is reportedly designed to get these products to patients as quickly as possible. The approval is a kind of "provisional license", the Asahi newspaper said, after the safety and efficacy of the treatment was judged based on data from fewer patients than in ordinary clinical trials for drugs.

A trial led by Kyoto University researchers indicated that the company's treatment was safe and successful in improving symptoms. The study involved seven Parkinson's patients aged between 50 and 69, with each receiving a total of either five million or 10 million cells implanted on both sides of the brain... The patients were monitored for two years and no major adverse effects were found, the study said. Four patients showed improvements in symptoms.
The article notes that "Worldwide, about 10 million people have the illness, according to the Parkinson's Foundation," while also notes that today's current therapies "improve symptoms without slowing or halting the disease progression..."

Fossil fuels produce NO2, which is linked to asthma attacks, bronchitis, and higher risks of heart disease and stroke, according the EV news site Electrek. But the nonprofit news site Grist.org notes a new analysis showing that those emissions decreased by 1.1% for every increase of 200 electric vehicles — across nearly 1,700 ZIP codes. "A pretty small addition of cars at the ZIP code level led to a decline in air pollution," said Sandrah Eckel, a public health professor at the University of Southern California's Keck School of Medicine and lead author of the study. "It's remarkable."
The study was done at the University of Southern California's medical school, by researchers using high-resolution satellite data, reports Electrek: The study, just published in The Lancet Planetary Health and partly funded by the National Institutes of Health, adds rare real-world evidence to a claim that's often taken for granted — that EVs don't just cut carbon over time, they also improve local air quality right now... The researchers ran multiple checks to make sure the trend wasn't driven by unrelated factors. They accounted for pandemic-era changes by excluding 2020 in some analyses and controlling for gas prices and work-from-home patterns. They also saw the expected counterexample: neighborhoods that added more gas-powered vehicles experienced increases in pollution. The findings were then replicated using updated ground-level air monitoring data dating back to 2012...

Next, the researchers plan to compare EV adoption with asthma-related emergency room visits and hospitalizations. If those trends line up, it could provide some of the clearest evidence yet of what we already know: that electrifying transportation doesn't just clean the air on paper; it improves public health in practice.
Thanks to long-time Slashdot reader jhoegl for sharing the article.

In a small double-blind clinical trial, a single intravenous dose of DMT produced rapid and clinically meaningful reductions in symptoms of major depressive disorder within a week, with effects lasting up to three months in some patients. "Unlike psilocybin and lysergic acid diethylamide ( LSD), whose effects can last for hours, intravenous DMT has a half-life of around five minutes," notes ScienceAlert. "Its psychedelic effects are correspondingly brief, potentially making it more practical to administer in clinical settings." From the report: "A single dose of DMT with psychotherapeutic support produced a rapid, significant reduction in depressive symptoms, sustained up to three months," writes a team led by neuroscientists David Erritzoe and Tommaso Barba of Imperial College London. [...] They recruited 34 participants with major depression and divided them into two groups of 17 for a double-blind, placebo-controlled trial.

In the first stage of the trial, one group received an intravenous dose of DMT, while the other received an active placebo. Neither the researchers nor the participants were informed which participants received the DMT. The doses took around 10 minutes to administer, and a therapist sat with each participant to ensure comfort and safety while the psychedelic effects were active, remaining silent throughout the treatment. The treatment was generally well tolerated. Most side effects were mild to moderate, and included nausea, temporary anxiety, and pain at the injection site. No serious adverse events related to the treatment were reported, although brief increases in heart rate and blood pressure were observed immediately after dosing.

In the second, open-label stage, two weeks after the first dose, all participants were given the opportunity to receive a dose of DMT. Participants were assessed before and at intervals after each dose using the Montgomery-Asberg Depression Rating Scale. Just a week after the first dose, participants who had received DMT had improved scores compared to the placebo group, and improvements were sustained during follow-up assessments.

Two weeks after the first dose, the participants who received DMT scored about seven points lower, on average, than those who received a placebo. On this commonly used clinical scale, a drop of that size is generally considered a meaningful reduction in symptom severity. There was no significant difference between patients who received one or two doses of DMT, suggesting a single dose may be sufficient. These effects persisted for up to three months, and some patients remained in remission for at least six months following the treatment. The findings have been published in Nature Medicine.

Longtime Slashdot reader walterbyrd shares a report from ABC News: In a study of nearly 28 million older Americans, long-term exposure to fine particle air pollution raised the risk of Alzheimer's disease. That link held even after researchers accounted for common conditions like high blood pressure, stroke and depression. Fine particle air pollution, known as PM2.5, consists of tiny particles in the air that come from car exhaust, power plants, wildfires, and burning fuels, according to the American Lung Association. They are small enough to travel deep into the lungs and even reach the bloodstream.

The research, conducted at Emory University and published in PLOS Medicine, tracked health data over nearly two decades to explore whether air pollution harms the brain indirectly by causing high blood pressure or heart disease, which, in turn, leads to dementia. However, these "middleman" conditions accounted for less than 5% of the connection between pollution and Alzheimer's, the research found. The researchers say this suggests that over 95% of the Alzheimer's risk comes from the direct impact of breathing in dirty air, likely through inflammation or damage to brain cells. "The relationship between PM2.5 and AD [Alzheimer's disease] has been shown to be pretty much linear," said Kyle Steenland, a professor in the departments of environmental health and epidemiology at the Rollins School of Public Health at Emory University, and senior author of the study. "The reason this is particularly important is that PM2.5 is known to be associated with high blood pressure, stroke and depression -- all of which are associated with AD. So, from a prevention standpoint, simply treating these diseases will not get rid of the problem. We have to address exposure to PM2.5."

Up to a third of people worldwide have shoulder pain; it's one of the most common musculoskeletal complaints. But medical imaging might not reveal the problem -- in fact, it could even cloud it. From a report: In a study published in JAMA Internal Medicine this week, 99 percent of adults over 40 were found to have at least one abnormality in a rotator cuff on magnetic resonance imaging (MRI). The rotator cuff is the group of muscles and tendons in a shoulder joint that keeps the upper arm bone securely in the shoulder socket -- and is often blamed for pain and other symptoms.

The trouble is, the vast majority of the people in the study had no problems with their shoulders. The finding calls into question the growing use of MRIs to try to diagnose shoulder pain -- and, in turn, the growing problem of overtreatment of rotator cuff (RC) abnormalities, which includes partial- and full-thickness tears as well as signs of tendinopathy (tendon swelling and thickening). "While we cannot dismiss the possibility that some RC tears may contribute to shoulder symptoms, our findings indicate that we are currently unable to distinguish clinically meaningful MRI abnormalities from incidental findings," the study authors concluded.

If you think your daily doses of espresso or Earl Grey sharpen your mind, you just might be right, new science suggests. The New York Times: A large new study provides evidence of cognitive benefits from coffee and tea -- if it's caffeinated and consumed in moderation: two to three cups of coffee or one to two cups of tea daily.

People who drank that amount for decades had lower chances of developing dementia than people who drank little or no caffeine, the researchers reported. They followed 131,821 participants for up to 43 years. "This is a very large, rigorous study conducted long term among men and women that shows that drinking two or three cups of coffee per day is associated with reduced risk of dementia," said Aladdin Shadyab, an associate professor of public health and medicine at the University of California, San Diego, who wasn't involved in the study.

The findings, published Monday in JAMA, don't prove caffeine causes these beneficial effects, and it's possible other attributes protected caffeine drinkers' brain health. But independent experts said the study adjusted for many other factors, including health conditions, medication, diet, education, socioeconomic status, family history of dementia, body mass index, smoking and mental illness.

Researchers at the University of Pennsylvania and University of Michigan "have created the world's smallest fully programmable, autonomous robots," according to a recent announcement.

The announcement calls them "microscopic swimming machines that can independently sense and respond to their surroundings, operate for months and cost just a penny each." Barely visible to the naked eye, each robot measures about 200 by 300 by 50 micrometers, smaller than a grain of salt. Operating at the scale of many biological microorganisms, the robots could advance medicine by monitoring the health of individual cells and manufacturing by helping construct microscale devices. Powered by light, the robots carry microscopic computers and can be programmed to move in complex patterns, sense local temperatures and adjust their paths accordingly... "We've made autonomous robots 10,000 times smaller," says Marc Miskin, Assistant Professor in Electrical and Systems Engineering at Penn Engineering and the papers' senior author. "That opens up an entirely new scale for programmable robots."
The announcement describes them as "the first truly autonomous, programmable robots at this scale" (as described in two recent academic articles). The team had to design a new propulsion system that utilized the unique locomotion physics in the microscopic realm, according to the university's announcement. So the robots "generate an electrical field that nudges ions in the surrounding solution." Those ions, in turn, push on nearby water molecules, animating the water around the robot's body. "It's as if the robot is in a moving river," says Miskin, "but the robot is also causing the river to move." The robots can adjust the electrical field that causes the effect, allowing them to move in complex patterns and even travel in coordinated groups, much like a school of fish, at speeds of up to one body length per second...

To be truly autonomous, a robot needs a computer to make decisions, electronics to sense its surroundings and control its propulsion, and tiny solar panels to power everything, and all that needs to fit on a chip that is a fraction of a millimeter in size. This is where David Blaauw's team at the University of Michigan came into action... The robots are programmed by pulses of light that also power them. Each robot has a unique address that allows the researchers to load different programs on each robot. "This opens up a host of possibilities," adds Blaauw, "with each robot potentially performing a different role in a larger, joint task."
Thanks to long-time Slashdot reader fahrbot-bot for sharing the news.

Ancient Slashdot reader erice shares the findings from a recent study showing that while AI helped researchers publish more often and boosted their careers, the resulting papers were, on average, less useful. "You have this conflict between individual incentives and science as a whole," says James Evans, a sociologist at the University of Chicago who led the study. From a recent IEEE Spectrum article: To quantify the effect, Evans and collaborators from the Beijing National Research Center for Information Science and Technology trained a natural language processing model to identify AI-augmented research across six natural science disciplines. Their dataset included 41.3 million English-language papers published between 1980 and 2025 in biology, chemistry, physics, medicine, materials science, and geology. They excluded fields such as computer science and mathematics that focus on developing AI methods themselves. The researchers traced the careers of individual scientists, examined how their papers accumulated attention, and zoomed out to consider how entire fields clustered or dispersed intellectually over time. They compared roughly 311,000 papers that incorporated AI in some way -- through the use of neural networks or large language models, for example -- with millions of others that did not.

The results revealed a striking trade-off. Scientists who adopt AI gain productivity and visibility: On average, they publish three times as many papers, receive nearly five times as many citations, and become team leaders a year or two earlier than those who do not. But when those papers are mapped in a high-dimensional "knowledge space," AI-heavy research occupies a smaller intellectual footprint, clusters more tightly around popular, data-rich problems, and generates weaker networks of follow-on engagement between studies. The pattern held across decades of AI development, spanning early machine learning, the rise of deep learning, and the current wave of generative AI. "If anything," Evans notes, "it's intensifying." [...] Aside from recent publishing distortions, Evans's analysis suggests that AI is largely automating the most tractable parts of science rather than expanding its frontiers.

An anonymous reader quotes a report from NPR: [I]t turns out that some genius dogs can learn a brand new word, like the name of an unfamiliar toy, by just overhearing brief interactions between two people. What's more, these "gifted" dogs can learn the name of a new toy even if they first hear this word when the toy is out of sight -- as long as their favorite human is looking at the spot where the toy is hidden. That's according to a new study in the journal Science. "What we found in this study is that the dogs are using social communication. They're using these social cues to understand what the owners are talking about," says cognitive scientist Shany Dror of Eotvos Lorand University and the University of Veterinary Medicine, Vienna. "This tells us that the ability to use social information is actually something that humans probably had before they had language," she says, "and language was kind of hitchhiking on these social abilities."

[...] "There's only a very small group of dogs that are able to learn this differentiation and then can learn that certain labels refer to specific objects," she says. "It's quite hard to train this and some dogs seem to just be able to do it." [...] To explore the various ways that these dogs are capable of learning new words, Dror and some colleagues conducted a study that involved two people interacting while their dog sat nearby and watched. One person would show the other a brand new toy and talk about it, with the toy's name embedded into sentences, such as "This is your armadillo. It has armadillo ears, little armadillo feet. It has a tail, like an armadillo tail." Even though none of this language was directed at the dogs, it turns out the super-learners registered the new toy's name and were later able to pick it out of a pile, at the owner's request.

To do this, the dogs had to go into a separate room where the pile was located, so the humans couldn't give them any hints. Dror says that as she watched the dogs on camera from the other room, she was "honestly surprised" because they seemed to have so much confidence. "Sometimes they just immediately went to the new toy, knowing what they're supposed to do," she says. "Their performance was really, really high." She and her colleagues wondered if what mattered was the dog being able to see the toy while its name was said aloud, even if the words weren't explicitly directed at the dog. So they did another experiment that created a delay between the dog seeing a new toy and hearing its name. The dogs got to see the unfamiliar toy and then the owner dropped the toy in a bucket, so it was out of sight. Then the owner would talk to the dog, and mention the toy's name, while glancing down at the bucket. While this was more difficult for dogs, overall they still could use this information to learn the name of the toy and later retrieve it when asked. "This shows us how flexible they are able to learn," says Dror. "They can use different mechanisms and learn under different conditions."

Scientists at Melbourne's Peter Doherty Institute for Infection and Immunity are working on a Crispr-based treatment -- delivered as a nasal spray or injection -- that could stop influenza infections by targeting the virus's RNA and disrupting its ability to replicate inside human cells.

The approach uses the Cas13 enzyme, a lesser-known cousin of the DNA-cutting Cas9, which can be engineered to seek out conserved regions of influenza's genetic code that are found in virtually all flu strains and are crucial to the virus's survival. The delivery mechanism would use lipid nanoparticles to ferry two molecular instructions to flu-infected cells in the respiratory tract: an mRNA that tells cells to produce Cas13 and a guide RNA that directs the enzyme to specific parts of the influenza virus's code.

Cas13 then cuts the viral RNA and effectively stops the infection at the genetic level, Sharon Lewin, the infectious diseases physician leading the project, told Wired. Early safety testing at Harvard's Wyss Institute used a "lung on a chip" model to examine whether human cells producing Cas13 could fight off flu strains including H1N1 and H3N2. The institute's founding director Donald Ingber says the studies showed no off-target effects.

An anonymous reader shared this report from the Independent: Candida auris, a type of invasive yeast that can cause deadly infections in people with weakened immune systems, has infected at least 7,000 people [in 2025] across 27 U.S. states, according to data from the Centers for Disease Control and Prevention. The fungus, which can spread easily in healthcare settings such as hospitals and nursing homes, is gaining virulence and spreading at an "alarming" rate, the CDC says. Some strains of the fungus are particularly troublesome — and even considered a superbug — because they're resistant to all types of antibiotics used to treat fungal infections, The Hill reports.

While healthy people may be able to fight off the infection on their own, the fungus can be deadly, especially in healthcare settings, where it can quickly spread amongst a vulnerable population. "If you get infected with this pathogen that's resistant to any treatment, there's no treatment we can give you to help combat it. You're all on your own," Melissa Nolan, an assistant professor of epidemiology and biostatistics at the University of South Carolina, told Nexstar...

A recent study found that Candida auris is gaining virulence and spreading rapidly, not just in the U.S., but also globally. Candida auris has already been found in at least 61 countries on six continents.
Some context from Newsweek: There are strategies available to combat Candida auris infection. While the superbug can develop ways to evade the immune response, vaccination and treatment strategies are possible, but researchers would like them to be strengthened. Four classes of antifungal drugs are currently available, with varying degrees of efficacy, and three new drugs are currently in trials or at newly approved stages

A Guardian investigation published Friday found that Google's AI Overviews -- the generative AI summaries that appear at the top of search results -- are serving up inaccurate health information that experts say puts people at risk of harm. The investigation, which came after health groups, charities and professionals raised concerns, uncovered several cases of misleading medical advice despite Google's claims that the feature is "helpful" and "reliable."

In one case described by experts as "really dangerous," Google advised people with pancreatic cancer to avoid high-fat foods, which is the exact opposite of what should be recommended and could jeopardize a patient's chances of tolerating chemotherapy or surgery. A search for liver blood test normal ranges produced masses of numbers without accounting for nationality, sex, ethnicity or age of patients, potentially leaving people with serious liver disease thinking they are healthy. The company also incorrectly listed a pap test as a test for vaginal cancer.

The Eve Appeal cancer charity noted that the AI summaries changed when running the exact same search, pulling from different sources each time. Mental health charity Mind said some summaries for conditions such as psychosis and eating disorders offered "very dangerous advice."

Google said the vast majority of its AI Overviews were factual and that many examples shared were "incomplete screenshots," adding that the accuracy rate was on par with featured snippets.

The International Publishers Association spent the past year promoting the slogan "Democracy depends on reading," but Atlantic senior editor Adam Kirsch argues that this utilitarian pitch fundamentally misunderstands why people become readers in the first place.

The most recent Survey of Public Participation in the Arts found that less than half of Americans read a single book in 2022, and only 38% read a novel or short story. A University of Florida and University College London study found daily reading for pleasure fell 3% annually from 2003 to 2023. Among 13-year-olds, just 14% read for fun almost every day in 2023, down from 27% a decade earlier.

Kirsch says to stop treating reading as civic medicine. "It would be better to describe reading not as a public duty but as a private pleasure, sometimes even a vice," he writes. When literature was considered transgressive, moralists couldn't stop people from buying dangerous books. Now that books are deemed virtuous, nobody picks them up. He points to Don Quixote and Madame Bovary -- novels whose protagonists are ruined by their reading habits. Great writers, he notes, never idealized literature the way educators do. The pitch to young readers should emphasize staying up late reading under the covers by flashlight, hoping nobody finds out.

The Wall Street Journal reports that a growing number of tech startups are stocking offices with free nicotine pouches as founders and employees chase sharper focus and stamina in hyper-competitive AI-era work environments. The Wall Street Journal reports: Earlier this year, two nicotine startups -- Lucy Nicotine and Sesh -- made branded vending machines filled with flavored products for analytics company Palantir Technologies. Both machines are in the company's Washington, D.C., offices. The pouches are free for employees and guests over the age of 21, a spokeswoman for Palantir said. Palantir pays to stock the nicotine products.

Alex Cohen, a startup founder based in Austin, Texas, said he was first exposed to nicotine pouches in the workplace after seeing tins of Zyns on the desks of his software engineers. His company, Hello Patient, makes AI-powered healthcare-communication software. "They were very productive, so I thought maybe there's something here," he said. Those engineers soon asked him if he could buy it for the office.

Cohen said he initially bought the nicotine pouches as a joke for social media. He posted a picture of a drawer in his startup's office filled with nicotine pouches made by different brands with the caption, "We're hiring." "Then, I accidentally got addicted," said Cohen. He said he uses around two to three pouches a day. His go-to flavors are mango or minty. Cohen said he has attention-deficit/hyperactivity disorder, or ADHD, and he has found that the pouches can provide a quick productivity boost. "It helps with reining in my focus because it is a stimulant," he said. Today, Hello Patient has a nicotine-pouch fridge in its office kitchen.

The U.S. has surpassed 2,000 measles cases for the first time in more than 30 years, according to data from the Centers for Disease Control and Prevention. From a report: As of Dec. 23, a total of 2,012 cases have been reported in the U.S. Of those cases, 24 were reported among international visitors to the U.S.